Bengaluru-based Biotech startup Eyestem has bagged INR 51 Crore in its Series A at a post-money valuation of $46.4 million funding round led by Biological E. Ltd, Alkem, NATCO, Anurag Bagaria and Karan Bagaria from Kemwell Biopharma. Existing investors–Endiya Partners and Kotak Private Equity also participated.
Eyestem has used this fresh fund to develop a scalable cell therapy platform to treat incurable diseases and democratize access to these newer technologies globally.
“We started EYESTEM with the sole objective of being able to mass-scale cell therapy products for diseases that afflict a large number of people in India and the world. Will focus on strengthening the therapy platform and moving forward the flagship product for dry AMD through preliminary clinical trials of an international standard,” said Dr. Jogin Desai, Founder and CEO, Eyestem.
Founded in 2016 by a top-class management team, Dr. Jogin Desai, Jogin Desai, Rajani Battu, with long-term vision is to create a global and scalable cell therapy platform to treat.